Você procurou por: fesoterodine (Maltês - Inglês)

fesoterodine fumarate
fesoterodine fumarate

pillola 1 fiha 4 mg fesoterodine fumarate
1 tablet contains 4 mg fesoterodine fumarate

is-sustanza attiva hi fesoterodine fumarate.
the active substance is fesoterodine fumarate.

fesoterodine u b’ hekk inaqqsu l- effett tiegħu:
fesoterodine and thus decrease its effect:

fesoterodine huwa antagonist kompetittiv speċifiku tar-riċettur muskariniku.
fesoterodine is a competitive, specific muscarinic receptor antagonist.

ir-relazzjoni mat-trattament ta’ fesoterodine m’hix ċara
the relation to fesoterodine treatment is unclear.

is- sustanza attiva f’ toviaz, fesoterodine, hija mediċina antikolinerġika.
the active substance in toviaz, fesoterodine, is an anticholinergic medicine.

toviaz 4 mg pilloli li jerħu l-mediċina bil-mod fesoterodine fumarate
toviaz 4 mg prolonged-release tablets fesoterodine fumarate

plaċebo fesoterodine fesoterodine komparatur plaċebo fesoterodine fesoterodine 4 mg 8 mg attiv 4 mg 8 mg
fesoterodine fesoterodine

fesoterodine ingħata mingħajr periklu fi studji kliniċi f’dożi sa 28 mg/jum.
fesoterodine has been safely administered in clinical studies at doses up to 28 mg/day.

livelli terapewtiċi fil-plażma jintlaħqu wara l-ewwel għotja ta’ fesoterodine.
therapeutic plasma levels are achieved after the first administration of fesoterodine.

m’hemmx tagħrif biżżejjed dwar l-użu ta’ fesoterodine waqt it-tqala.
there are no adequate data from the use of fesoterodine in pregnant women.

il-farmakokinetika ta’ fesoterodine m’hix affettwata b’mod sinifikanti minn età u sess.
the pharmacokinetics of fesoterodine are not significantly influenced by age and gender.

il-farmakokinetiċi ta’ fesoterodine f’pazjenti li għandhom indeboliment epatiku serju ma ġewx studjati.
pharmacokinetics of fesoterodine in patients with severe hepatic impairment have not been studied.

wara l-għoti mill-ħalq, fesoterodine huwa idrolizzat malajr u estensivament biex jifforma l-metabolit attiv.
after oral administration, fesoterodine is rapidly and extensively hydrolysed to its active metabolite.

18 metaboliżmu wara l- għoti mill- ħalq, fesoterodine huwa idrolizzat malajr u estensivament biex jifforma l- metabolit attiv.
18 n-desisopropyl metabolite with involvement of cyp2d6 and cyp3a4.

fesoterodine u solifenacin huma kontraindikati f’pazjenti b’indeboliment tal-kliewi (ara sezzjoni 4.3).
fesoterodine and solifenacin are contraindicated in patients with renal impairment (see section 4.3).

fesoterodine jista jnaqqas l-effectt ta’ prodotti mediċinali li jistimulaw il-moviment tal-passaġġ gastrointestinali bħal metoclopramide.
fesoterodine may reduce the effect of medicinal products that stimulate the motility of the gastro-intestinal tract, such as metoclopramide.

f’każ ta’ doża eċċessiva ta’ fesoterodine, ittratta b’ħasil ta’ l-istonku u agħti charcoal attivat.
in the event of fesoterodine overdose, treat with gastric lavage and give activated charcoal.

fil-preżenza ta’ fesoterodine ma hemm l-ebda tibdil fil-konċentrazjonijiet fil-plażma ta’ kontraċettivi kumbinati li fihom ethinylestradiol u levonorgestrel.
in the presence of fesoterodine there are no changes in the plasma concentrations of combined oral contraceptives containing ethinylestradiol and levonorgestrel.